Orchestra BioMed Q2 Revenue Collapses, Loss Widens; Cash Runway Extended to Q4 2027
OBIO has more than doubled off its 52-week low of $2.2.
Summary
Orchestra BioMed's Q2 revenue evaporated to $88K as partnership income dried up, while the net loss widened to $23.8M. New financing of $40.9M extended the cash runway into late 2027, buying time for pivotal trial readouts.
Key Events · Earnings and Guidance · OBIO
-
Revenue Collapse
Total Q2 revenue fell to $88K from $836K a year ago. Partnership revenue dropped to zero after the Terumo agreement termination; product revenue halved to $88K.
-
Loss Widens on Higher R&D
Net loss attributable to common stockholders widened to $24.1M from $19.4M, driven by a 20% increase in R&D expenses to $16.6M as the BACKBEAT and Virtue trials advance.
-
Cash Runway Extended to Q4 2027
Ended Q2 with $110.0M in cash and marketable securities. New financing of $40.9M — a $20M Medtronic convertible loan and a $15M Ligand royalty tranche — funds operations into the fourth quarter of 2027.
-
CFO Terminates 10b5-1 Plan
CFO Andrew Taylor terminated a pre-existing 10b5-1 trading plan for 84,000 shares on May 27, 2026, removing a near-term selling overhang.
Analysis · OBIO · Industrial Applications And Services
Orchestra BioMed's Q2 2026 results reveal a near-total revenue collapse — partnership revenue fell to zero after the Terumo agreement termination, and product revenue halved. The net loss widened to $23.8 million from $19.4 million a year ago, driven by a 20% jump in R&D spending as the BACKBEAT and Virtue pivotal trials advance. During the quarter, the company raised $40.9 million in new financing — a $20 million Medtronic convertible loan and a $15 million Ligand royalty tranche — and ended June with $110 million in cash and securities, funding operations into Q4 2027. The CFO terminated a pre-existing 10b5-1 trading plan, removing a near-term overhang. Inclusion in the Russell indexes may provide passive buying support. The cash cushion removes immediate survival risk, but the revenue vacuum and rising losses underscore the binary nature of the pipeline — the company is entirely dependent on clinical trial success for value creation.
At the time of this filing, OBIO was trading at $4.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $267.1M. The 52-week trading range was $2.20 to $5.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.